ID

23837

Description

Study part: Esophagogastroduodenoscopy Week 38/ Early Withdrawal visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Keywords

  1. 7/15/17 7/15/17 -
Copyright Holder

GlaxoSmithKline

Uploaded on

July 15, 2017

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Esophagogastroduodenoscopy Week 38 Mepolizumab HES NCT00086658

Esophagogastroduodenoscopy Week 38

ESOPHAGOGASTRODUODENOSCOPY
Description

ESOPHAGOGASTRODUODENOSCOPY

Alias
UMLS CUI-1
C0079304
Subject Identifier
Description

Subject Identifier

Data type

text

Alias
UMLS CUI [1]
C2348585
Date of assessment
Description

Date of assessment

Data type

date

Alias
UMLS CUI [1]
C2985720

Similar models

Esophagogastroduodenoscopy Week 38

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
ESOPHAGOGASTRODUODENOSCOPY
C0079304 (UMLS CUI-1)
Subject Identifier
Item
Subject Identifier
text
C2348585 (UMLS CUI [1])
Date of assessment
Item
Date of assessment
date
C2985720 (UMLS CUI [1])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial